GSK plc

GSK plc is a global healthcare company focused on the research, development, and manufacture of vaccines, specialty medicines, and general medicines. Its specialty medicines portfolio includes treatments for oncology, respiratory/immunology, inflammation, and HIV, as well as inhaled medicines for conditions like respiratory eosinophil-driven diseases, lupus, and ovarian cancer. The company also produces vaccines for shingles, meningitis, RSV, seasonal influenza, hepatitis, and many other diseases. In addition, GSK offers general medicines for asthma, COPD, bacterial infections, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. The company is also involved in discovering and developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases.

GSK plc is listed on the New York Stock Exchange (NYSE) under the ticker symbol GSK. Its shares trade in US dollars (USD). The company is headquartered in London, United Kingdom, and its primary listing is on the London Stock Exchange, but it also has an American Depositary Receipt (ADR) program on the NYSE, making it accessible to US investors in USD.

GSK plc operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This means GSK is a diversified pharmaceutical company that develops, produces, and markets a wide range of medicines and vaccines. As a drug manufacturer, it covers both branded prescription drugs and over-the-counter products, with a strong emphasis on vaccines and specialty therapeutics for chronic and infectious diseases.

GSK plc is headquartered in London, United Kingdom, and was founded in 1715. The company operates globally, serving patients and healthcare providers worldwide. Its business is organized into Commercial Operations and Total R&D segments, with a focus on vaccines, specialty medicines, and general medicines. GSK has collaborations with other companies, such as a partnership with CureVac to develop mRNA vaccines for infectious diseases and a strategic alliance with AN2 Therapeutics for new therapies for tuberculosis.

GSK generates revenue through the sale of its pharmaceutical products, including vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes products for shingles, meningitis, RSV, influenza, hepatitis, and human papillomavirus, among others. Specialty medicines target areas like HIV, respiratory diseases, lupus, and certain cancers. General medicines address common conditions such as asthma, COPD, and bacterial infections. The company also earns from research collaborations and licensing agreements, such as its partnership with CureVac for mRNA vaccines. GSK's business model focuses on innovation in R&D to bring new therapies to market, supported by a global commercial infrastructure.